From Analysis:
What determines the optimal timing and dosing of ketogenic interventions for neuroprotection?
While ketone metabolism was discussed as therapeutic, the debate revealed no clear framework for when and how much ketosis provides benefit vs harm. The 'metabolic steal syndrome' hypothesis suggests timing could be critical but remains untested. Source: Debate session sess_SDA-2026-04-02-gap-v2-5d0e3052 (Analysis: SDA-2026-04-02-gap-v2-5d0e3052)
Molecular Mechanism and Rationale
The astrocyte-neuron metabolic coupling system represents one of the most sophisticated energy management networks in the central nervous system, with β-hydroxybutyrate dehydrogenase 1 (BDH1) serving as a critical regulatory node in this metabolic orchestra. BDH1, located on the inner mitochondrial membrane, catalyzes the reversible oxidation of β-hydroxybutyrate to acetoacetate, representing the rate-limiting step in ketone body utilization within astrocytes. This enzymatic activity directly interfaces with the astrocyte-neuron lactate shuttle (ANLS), where astrocytes typically consume glucose via glycolysis to produce lactate for neuronal oxidative metabolism.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["Low-Dose BHB
0.5-1.0 mM"]
B["Astrocytic Lactate Production
Preserved"]
C["Astrocyte-Neuron
Lactate Shuttle"]
D["Neuronal Support
Optimal"]
E["High-Dose BHB
>>2.0 mM"]
F["Complete Astrocytic
Glycolysis Shutdown"]
G["Metabolic Steal Syndrome"]
H["Neuronal Energy Deficit"]
A --> B
B --> C
C --> D
E --> F
F --> G
G --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style D fill:#1b5e20,stroke:#81c784,color:#81c784
Median TPM across 13 brain regions for BDH1 from GTEx v10.
Based on my research into ketone metabolism, neuroprotection, and the metabolic steal syndrome hypothesis, I'll generate novel therapeutic hypotheses for optimal timing and dosing of ketogenic interventions.
Based on my analysis of the available research, here is my critical evaluation of each hypothesis:
Specific Weaknesses:
Based on my analysis of the target proteins and therapeutic landscape, here's a comprehensive assessment of the practical feasibility for each surviving hypothesis:
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 💬 | Debate Round | $0.854 | ▲ 53.5% | market_dynamics | 2026-04-17 07:07 |
| 📊 | Score Update | $0.556 | ▼ 2.0% | market_dynamics | 2026-04-17 04:54 |
| 📄 | New Evidence | $0.568 | ▼ 3.5% | market_dynamics | 2026-04-17 03:48 |
| 📄 | New Evidence | $0.588 | ▲ 1.3% | market_dynamics | 2026-04-17 03:01 |
| 📄 | New Evidence | $0.581 | ▲ 11.6% | market_dynamics | 2026-04-17 02:53 |
| 💬 | Debate Round | $0.520 | ▲ 1.1% | market_dynamics | 2026-04-17 01:36 |
| 💬 | Debate Round | $0.515 | ▼ 11.9% | market_dynamics | 2026-04-17 00:46 |
| 📊 | Score Update | $0.584 | ▼ 13.0% | market_dynamics | 2026-04-17 00:10 |
| 📊 | Score Update | $0.671 | market_dynamics | 2026-04-16 23:39 |
No clinical trials data available
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
| Date | Signal Price | Score |
|---|---|---|
| 2026-04-17T09:10 | $0.673 | 0.483 |
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for BDH1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
__hydroxybutyrate["β-hydroxybutyrate"] -.->|inhibits| HDAC2["HDAC2"]
__hydroxybutyrate_1["β-hydroxybutyrate"] -.->|inhibits| HDAC3["HDAC3"]
__hydroxybutyrate_2["β-hydroxybutyrate"] -->|activates| BDNF_expression["BDNF expression"]
__hydroxybutyrate_3["β-hydroxybutyrate"] -->|modulates| autophagy["autophagy"]
__hydroxybutyrate_4["β-hydroxybutyrate"] -->|regulates| mitochondrial_metabolism["mitochondrial metabolism"]
__hydroxybutyrate_5["β-hydroxybutyrate"] -->|modulates| epigenetic_regulation["epigenetic regulation"]
__hydroxybutyrate_6["β-hydroxybutyrate"] -->|protective against| ischemic_brain_injury["ischemic brain injury"]
__hydroxybutyrate_7["β-hydroxybutyrate"] -.->|reduces| oxidative_stress["oxidative stress"]
__hydroxybutyrate_8["β-hydroxybutyrate"] -.->|reduces| neuroinflammation["neuroinflammation"]
__hydroxybutyrate_9["β-hydroxybutyrate"] -.->|inhibits| astrocytic_glucose_consum["astrocytic glucose consumption"]
__hydroxybutyrate_10["β-hydroxybutyrate"] -.->|inhibits| astrocytic_glycolysis["astrocytic glycolysis"]
__hydroxybutyrate_11["β-hydroxybutyrate"] -->|regulates| IRAKM["IRAKM"]
style __hydroxybutyrate fill:#4fc3f7,stroke:#333,color:#000
style HDAC2 fill:#4fc3f7,stroke:#333,color:#000
style __hydroxybutyrate_1 fill:#4fc3f7,stroke:#333,color:#000
style HDAC3 fill:#4fc3f7,stroke:#333,color:#000
style __hydroxybutyrate_2 fill:#4fc3f7,stroke:#333,color:#000
style BDNF_expression fill:#4fc3f7,stroke:#333,color:#000
style __hydroxybutyrate_3 fill:#4fc3f7,stroke:#333,color:#000
style autophagy fill:#81c784,stroke:#333,color:#000
style __hydroxybutyrate_4 fill:#4fc3f7,stroke:#333,color:#000
style mitochondrial_metabolism fill:#4fc3f7,stroke:#333,color:#000
style __hydroxybutyrate_5 fill:#4fc3f7,stroke:#333,color:#000
style epigenetic_regulation fill:#81c784,stroke:#333,color:#000
style __hydroxybutyrate_6 fill:#4fc3f7,stroke:#333,color:#000
style ischemic_brain_injury fill:#ef5350,stroke:#333,color:#000
style __hydroxybutyrate_7 fill:#4fc3f7,stroke:#333,color:#000
style oxidative_stress fill:#4fc3f7,stroke:#333,color:#000
style __hydroxybutyrate_8 fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammation fill:#4fc3f7,stroke:#333,color:#000
style __hydroxybutyrate_9 fill:#4fc3f7,stroke:#333,color:#000
style astrocytic_glucose_consum fill:#4fc3f7,stroke:#333,color:#000
style __hydroxybutyrate_10 fill:#4fc3f7,stroke:#333,color:#000
style astrocytic_glycolysis fill:#81c784,stroke:#333,color:#000
style __hydroxybutyrate_11 fill:#4fc3f7,stroke:#333,color:#000
style IRAKM fill:#4fc3f7,stroke:#333,color:#000
metabolic neuroscience | 2026-04-03 | completed
No comments yet. Be the first to comment!